title: Colchicine to Reduce Atrial Fibrillation in the Postoperative Period of Myocardial Revascularization.
abstract: BACKGROUND
  The high prevalence of atrial fibrillation (AF) in the postoperative period of myocardial revascularization surgery increases morbidity and mortality.
  
  
  OBJECTIVE
  To assess the efficacy of colchicine to prevent AF in the postoperative period of myocardial revascularization surgery, the impact of AF on hospital length of stay and death, and to identify its risk factors.
  
  
  METHODS
  Between May 2012 and November 2013, 140 patients submitted to myocardial revascularization surgery were randomized, 69 to the control group and 71 to the colchicine group. Colchicine was used at the dose of 1 mg orally, twice daily, preoperatively, and of 0.5 mg, twice daily, until hospital discharge. A single dose of 1 mg was administered to those admitted 12 hours or less before surgery.
  
  
  RESULTS
  The primary endpoint was AF rate in the postoperative period of myocardial revascularization surgery. Colchicine group patients showed no reduction in AF incidence as compared to control group patients (7.04% versus 13.04%, respectively; p = 0.271). There was no statistically significant difference between the groups regarding death from any cause rate (5.6% versus 10.1%; p = 0,363) and hospital length of stay (14.5 ± 11.5 versus 13.3 ± 9.4 days; p = 0.490). However, colchicine group patients had a higher infection rate (26.8% versus 8.7%; p = 0.007).
  
  
  CONCLUSIONS
  The use of colchicine to prevent AF after myocardial revascularization surgery was not effective in the present study. Brazilian Registry of Clinical Trials number RBR-556dhr.
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: Camila Stuchi
authors.initials: CS
authors.lastname: Zarpelon
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: Miguel Chomiski
authors.initials: MC
authors.lastname: Netto
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: José Carlos Moura
authors.initials: JC
authors.lastname: Jorge
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: Cátia Carolina
authors.initials: CC
authors.lastname: Fabris
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: Dieli
authors.initials: D
authors.lastname: Desengrini
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: Mariana da Silva
authors.initials: Mda S
authors.lastname: Jardim
authors.affiliation: Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
authors.forename: Diego Guedes da
authors.initials: DG
authors.lastname: Silva
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control*; D003078:Colchicine / Q000494:pharmacology / Q000627:therapeutic use*; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000009:adverse effects*; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D003078:Colchicine